

Index

A

Acetaldehyde, 8
Acetaminophen, 416
Acute adverse event, 345
Adenoid squamous cell carcinoma, 51–53
Adenosquamous carcinoma, 52, 53
Adipofasciomusculocutaneous flap, 248
Adjuvant analgesics, 418
Adjuvant concurrent chemoradiotherapy, 307
Adult T-cell leukemia (ATL), 9
Advanced oral cancer, 319
Adverse events, 295
Aesthetic contour reconstruction, 260
Afatinib, 315
Ageusia, 336
Alcohol, 7, 95
Aldehyde dehydrogenase 2 (ALDH2), 9
Alternate forms, 405–406
Angiogenesis, 65–69, 71, 72
Anterolateral neck, 225
Apron flap, 246
Arrhythmias, 418
Articulation, 340
ATL. *See* Adult T-cell leukemia (ATL)
Au-198, 286

B

Bacteremia, 340
Bak, 67
Basaloid squamous cell carcinoma, 51, 53
Bax, 67
B-cell lymphoma-2 (Bcl-2), 67
Bcl-XL, 67
Betel quid, 94
Biopsy, 58
Bladder cancer, 7
Blurred vision, 418
Bone absorption type, 189
Bone resorption
 depth, 189
 image classification, 47
Brachial plexus, 343
Brachytherapy, 286
Bragg peak, 299
Breakthrough pain, 415, 417
Brinkman index, 8
Buccal mucosa, 24
Buccal mucosa cancer, 37, 146–148, 197–198
 betel nut, 5
 chewing tobacco, 5

C

Candida infection, 339
Carbon ion radiotherapy (CIRT), 298
Carboplatin, 312
Carcinoma in situ (CIS), 41–44, 86
 basaloid type, 42
 differentiated type, 42–44
Carcinomas
 of buccal mucosa, 160
 of floor of the mouth, 161–162, 195
 of lip, 166
 of lower alveolus and gingiva, 160
 of palate, 161
 of tongue, 161
 of upper alveolus and gingiva, 160
Caspase, 67, 72
CBCT. *See* Cone-beam CT (CBCT)
CDDP, 323
Central pain, 414
Cervical island flap, 246–250
Cervical lymph node metastasis, 159–160
Cervical plexus, 341
Cesium-137, 286
Cetuximab, 311, 313
Cheek, 233, 250
Cheilion, 269, 270
Chemoradiation, 225
Chemoradiotherapy, 286
Chemotherapy-induced oral mucositis, 355
Chronic hyperplastic candidiasis, 163
CIRT. *See* Carbon ion radiotherapy (CIRT)
CIS. *See* Carcinoma in situ (CIS)
Cisplatin, 312
Clinical diagnosis of RSD, 237
Clinical target volume (CTV), 287
Clinical types, 26–30, 91
 endophytic type, 26
 exophytic type, 26
 superficial type, 26
c-Met, 65, 66
Codeine, 416
Colorimeter, 87
Colorimetry, 87
Comitant vein, 235
Compound operation, 196
Computed tomography (CT), 100, 223
Computer-aided design, 265
Computer-aided virtual preplanning, 265
Conceptual and measurement model, 405
Concurrent chemoradiotherapy, 310–311
Cone-beam CT (CBCT), 100

- Constipation, 416, 418
 Corticosteroid, 418
 Cranial nerves, 341
 Cricopharyngeal myotomy, 240
 Crown prosthesis, 353
 CT perfusion (CTP), 100
 CTV. *See* Clinical target volume (CTV)
 Cubital fossa, 235
 Cultural and language adaptations/translations, 406
 Cumulative malignant transformation rate, 88
 Cyclin D1, 64–66
 Cyclooxygenase-2 (COX-2), 64, 69, 71
- D**
 Decalcification methods, 59
 Dental development abnormalities, 350
 Dental implantation, 353
 Dental implants, 256, 261, 269
 Dental restoration, 353
 Dental X-ray, 99
 Dermatitis, 295
 Diagnosis, 84–85
 Diffusion-weighted MRI, 101
 Disability, 231–232
 Disarticulation, 341
 Disease-specific questions, 260
 Distant metastasis, 160
 M factor, 126
 Distraction osteogenesis, 256
 Dizziness, 417
 DNA methylation, 69
 DOC. *See* Dose of docetaxel (DOC)
 Docetaxel, 312
 DOP-PMMC flap. *See* Double pedicled pectoralis major musculocutaneous flap (DOP-PMMC flap)
 Dose of docetaxel (DOC), 323
 Double-barreled vascularized fibula graft, 267–270
 Double cancer, 7, 13–16
 Double pedicled (DOP) flap, 242–246
 Double pedicled pectoralis major musculocutaneous flap (DOP-PMMC flap), 245
 Drooling, 254
 Drowsiness, 417, 418
 Dry mouth, 418
 Duloxetine, 418
 Dysarthria, 343
 Dysgeusia, 295, 336, 339
 Dyspnea, 413
- E**
 Early cancer, 9
 E-cadherin, 65, 68–70, 73
 Economic and/or vocational status and factors, 404
 ECS. *See* Extracapsular spread (ECS)
 EGFL7. *See* Epidermal growth factor-like domain 7 (EGFL7)
 EGFR. *See* Epidermal growth factor receptor (EGFR)
 Elective neck
 dissection, 227
 irradiation, 227
 Elective treatment, 226
 Electron beam therapy, 291
 EMT. *See* Epithelial-mesenchymal transition (EMT)
 END. *See* Extended neck dissection (END)
 Endodontic treatment, 353
 End-of-dose pain, 417
 End-of-life care, 414
 Endophytic type, 158
 Epidermal growth factor-like domain 7 (EGFL7), 72
 Epidermal growth factor receptor (EGFR), 64, 65, 73, 311
 Epithelial dysplasia, 86
 Epithelial-mesenchymal transition (EMT), 67–70
 Epithelial precursor lesions, 86
 Erlotinib, 65
 Erythroplakia, 13, 83, 94, 163
 Erythroplasia of Queyrat, 94
 Esophageal cancer, 7
 Etiological factors, 84
 European organization for research and treatment of cancer QOL questionnaire (EORTC QLQ)-C30, 407
 Evidence-based medicine (EBM), 404
 Exophytic type, 158
 Extended neck dissection (END), 225
 External–natural environment, 404
 External radiation therapy, 286
 External–social environment, 404
 Extracapsular nodal extension, 307
 Extracapsular spread (ECS), 224
- F**
 Face scales, 415
 Facial appearance, 267
 Facial artery, 247
 Facial contour, 258
 Facial nerve, 342
 Facial nodes, 226
 Facial reconstruction, 232
 Facial unit, 233
 Fas, 67
 Fas ligand (FasL), 67
 Fatigue, 413
 Federation Dentaire Internationale (FDI), 2
 Fentanyl, 416
 Fibular/scapular bone, 254, 257
 Field cancerization, 7
 Fine-needle aspiration (FNA), 223
 Five-year survival rate, 14
 Floor of mouth (FOM), 24
 cancer, 37, 39, 144–146
 Flowchart, 84
 FNA. *See* Fine-needle aspiration (FNA)
 FOM. *See* Floor of mouth (FOM)
 Forearm, 233
 Functional and aesthetic reconstruction, 250–254
 Functional assessment of cancer therapy scale general version (FACT-G), 260, 407–408
 Functional (unit) reconstruction, 261–263
 Fungal infections, 335
- G**
 Gabapentin, 418
 Gag cough reflex, 336
 Gastric cancer, 7
 Gastrostomy, 340
 Gefitinib, 65
 Gene polymorphism of glutathione S-transferase M1 (GSTM1), 9
 General QOL questionnaire, 406–407
 Genetic alterations, 63–64
 Gingival carcinoma, 136–143

Gingivectomy, 186
 Glossopalatal closure, 238
 Glucose transporter 1 (GLUT-1), 69
 Gross tumor volume (GTV), 287
 GSTM1. *See* Gene polymorphism of glutathione S-transferase M1 (GSTM1)
 GTV. *See* Gross tumor volume (GTV)

H

Hallmarks of cancer cell model, 65
 Hammock technique, 240
 Hard palate, 25
 cancer, 40, 190–195
 Harnsberger's fascia classification, 248
 Head and neck cancer, 2, 9, 13, 14
 Health-related QOL (HRQOL), 403
 Hemiglossectomy, 176
 Hemimandibulectomy, 258–261
 Hepatocyte growth factor (HGF), 65, 69
 HER, 65
 HGF. *See* Hepatocyte growth factor (HGF)
 High-dose rate (HDR) brachytherapy, 292
 High-mobility group box 1 (HMGB1), 71
 Histological grading, 44
 Histone deacetylation, 69
 Histopathological malignancy, 190
 HMGB1. *See* High-mobility group box 1 (HMGB1)
 Homogeneous leukoplakia, 85, 164
 Hook-shaped catheter, 322
 Horner's syndrome, 343
 HPV. *See* Human papillomavirus (HPV)
 H-Ras, 65
 HRQOL. *See* Health-related QOL (HRQOL)
 hTERT. *See* Human telomerase reverse transcriptase (hTERT)
 Human epidermal growth factor, 65, 73
 Human papillomavirus (HPV), 9, 64–67, 94
 Human telomerase reverse transcriptase (hTERT), 67
 Hyperbaric oxygen (therapy), 338, 353, 354
 Hyperthermia (HT), 328
 Hypofractionations, 302
 Hypoglossal nerve, 343
 Hypoplasia, 350
 Hypoxia-inducible factor-1 (HIF-1), 66, 68, 69

I

IMRT. *See* Intensity-modulated radiation therapy (IMRT)
 Incident pain, 417
 Individual screening, 16
 Induction chemotherapy, 311
 Indurative type, 157
 Infrahyoid muscles, 240
 Integrin, 68–69
 Intensity-modulated radiation therapy (IMRT), 289–291
 Internal mammary artery, 245
 International Agency for Research on Cancer (IARC), 8
 Interpretability, 405
 Intra-arterial chemotherapy, 321
 Intra-arterial infusion, 286
 Intraoral cone therapy, 286
 Intraoral US, 101
 Invasion depth, 26, 39, 40, 58
 images of mandibular resorption, 32
 Invasion route, 35–40, 49
 Iodine staining, 87
 Iridium-192, 286

K

Karnofsky performance status (KPS), 407
 Kidney cancer, 7
 K-Ras, 65, 72

L

Laryngectomy, 184
 Larynx cancer, 7
 Laser, 93
 Late adverse event, 348
 Lateral thoracic artery, 244
 LET. *See* Linear energy transfer (LET)
 Leukoplakia, 6, 12, 13, 15, 18, 83, 84, 163
 Leukoplakic type, 158
 Level classification, 126–127
 Lichen planus, 18
 Linear energy transfer (LET), 299
 Lingual nerve, 342
 Lip, 254
 cancer, 5, 6
 switch flap, 254
 Liver cancer, 7
 Ljubljana classification, 86
 Long term complications, 340
 Loss of taste, 339
 Low-dose rate (LDR) brachytherapy, 292
 Lower gingiva, 24
 cancer, 35, 184
 Lymphangiogenesis, 65, 67–69, 71–73
 Lymphatic vessel invasion, 52
 Lymph node metastasis, 54–55, 149–155
 extranodal invasion, 55
 level classification, 55
 Lymph nodes (N) factor, 126

M

Magnetic resonance imaging (MRI), 100–101, 223
 Malabsorption, 416
 Malignancy
 within bone, 165
 of maxillary sinus, 166
 Malignant lymphoma, 160, 164
 Malignant melanoma, 165–166
 Malignant transformation, 88–89
 period, 92
 rate, 88
 Mandibular canal, 49
 Mandibular gingival cancer, 5
 Mandibular reconstruction, 263–267
 Mandibulectomy, 187
 MAPK. *See* Mitogen-activated kinase protein (MAPK)
 Marginal mandibular branch, 342
 Marginal mandibular resection, 256
 Marginal mandibulectomy, 186, 196
 Mass screening, 16
 Masticatory difficulties, 341
 Masticatory function, 261
 Mathes's type II, 247
 Matrix metalloproteinase (MMP), 65, 68, 70–72
 Maxillary gingival cancer, 5, 6
 Maxillary reconstruction, 257
 Maxillary sinus cancer, 5, 6
 Maxillofacial reconstructions, 266
 Maxillomandibular reconstruction, 254–270
 Medial cubital vein, 234

Medical outcomes study 36-item short form, 407
 Melanoma inhibitory activity (MIA), 71–72
 MIA. *See* Melanoma inhibitory activity (MIA)
 MicroRNAs (miRNAs), 70
 Microscopic resection margin, 307
 miR-126, 72–73
 Mitogen-activated kinase protein (MAPK), 71, 72
 Mixed pain, 414
 MMP. *See* Matrix metalloproteinase (MMP)
 Model-based surgery, 265
 Mode of invasion, 26, 47, 48
 Mode of mandibular invasion, 47, 49, 50
 Modified radical neck dissection (MRND), 225
 Mold therapy, 293–294
 Molecular targeted drug, 311
 Money-pouch-like reconstruction method, 240
 Morphine, 416
 Morphine-6-glucuronide (M6G), 416
 Moth-eaten type, 159
 MRI. *See* Magnetic resonance imaging (MRI)
 MRND. *See* Modified radical neck dissection (MRND)
 Mucositis, 295, 335–336, 413
 scale, 336
 Multiple cancer, 13–16
 Multiple leukoplakia, 93
 Multiple oral cancers, 56
 Myelosuppression, 340

N

NAC. *See* Neoadjuvant chemotherapy (NAC)
 Nasogastric tube, 340
 Nausea, 340, 416, 417
 and vomiting, 418
 N3 cervical lymph node metastases, 329
 Neoadjuvant chemotherapy (NAC), 295, 311–312
 Neural invasion, 52
 Neuroanastomosis, 240
 Neurologic complications, 341–343
 Neuropathic pain, 414, 415, 418
 Neuropathy, 413
 NFκB. *See* Nuclear factor-kappa B (NFκB)
 NHRQOL. *See* Non-health-related QOL (NHRQOL)
 Nociceptive, 414
 Nodal groups/levels, 221
 Non-health-related QOL (NHRQOL), 403
 Non-homogeneous leukoplakia, 85, 164
 erythroleukoplakia, 86
 nodular, 86
 ulcerated, 86
 verrucous, 86
 Non-steroid anti-inflammatory drugs (NSAIDs), 416
 N-Ras, 65
 NSAIDs. *See* Non-steroid anti-inflammatory drugs (NSAIDs)
 Nuclear factor-kappa B (NFκB), 65, 66, 71
 Numeric rating scales, 415

O

OAR. *See* Organs at risk (OAR)
 OER. *See* Oxygen enhancement ratio (OER)
 OIN. *See* Oral intraepithelial neoplasia (OIN)
 Open biopsy, 224
 Opioid switching, 418
 Opioid titration, 416
 OPMDs. *See* Oral potentially malignant disorders (OPMDs)

Oral and dental management, 350–352
 Oral and maxillofacial reconstruction, 231
 Oral cancer, 169
 drinking, 3
 epidemiology, 1–19
 prevention, 2
 screening, 16–19
 smoking, 3
 staging, 102, 126–127
 Oral care, 356–357
 Oral commissure, 233, 250, 254, 255
 Oral floor cancer, 5, 6
 Oral hygiene, 355
 Oral intraepithelial neoplasia (OIN), 41–46
 basaloid type, 42
 differentiated type, 42–44
 Oral lichen planus, 163, 164
 Oral mucositis, 345
 Oral potentially malignant disorders (OPMDs), 83–96
 Oral squamous cell carcinoma (OSCC), 84, 221
 development, 87
 treatment, 93–94
 Organ preservation, 319
 Organs at risk (OAR), 287
 ORN. *See* Osteoradionecrosis (ORN)
 Oromandibular reconstruction, 238
 Oropharyngeal cancer, 2
 Orthopantomography, 99
 OSCC. *See* Oral squamous cell carcinoma (OSCC)
 Oscillating vein, 235
 Osteomyelitis, 295, 339
 Osteoradionecrosis (ORN), 286, 337–339, 348–350, 353, 354
 Osteotomies, 265
 Osteotomy guide template, 266, 268
 Oxycodone, 416
 Oxygen enhancement ratio (OER), 292

P

p53, 64, 66–67
 Pack-years, 8
 Paclitaxel, 312
 Pain, 413
 intensity, 415
 on mobilization, 415
 at rest, 415
 Pain management principles
 attention to detail, 415
 by the clock, 415
 for the individual, 415
 by the ladder, 415
 by the mouth, 415
 Palatal lesions in reverse smokers, 83
 Palate cancer, 5, 6
 Palliative care team, 414
 Palliative chemotherapy, 312–315
 Palpation, 223
 Pancreas cancer, 7
 Panitumumab, 314
 Papillary squamous cell carcinoma, 52, 53
 Papillary type, 158
 Papilloma, 163
 Partial glossectomy, 176
 Partial maxillectomy, 193
 Particle therapy, 298
 Particulate cancellous bone and marrow (PCBM), 241, 256–258

- Pectoralis major musculocutaneous (PMMC) flap, 242, 259
 Performance status scale (PSS), 260
 Periodontal disease, 347–348
 Periodontal membrane, 49
 Periodontal treatment, 353
 Personal–internal, 404
 Personal–social, 404
 PET–CT, 101, 223
 Pharynx cancer, 7
 Phosphatase and tensin homolog (PTEN), 65–67, 70
 Phosphatidylinositol-3-kinase (PI3K), 65, 67, 72
 Phrenic nerve, 343
 p16^{INK4A}, 67
 Planning target volume (PTV), 287
 Plaster of Paris, 267
 Platysma flap, 246–249
 Platysma myocutaneous flap, 248
 Ploidy, 64
 PMDs. *See* Potentially malignant disorders (PMDs)
 PMMC flap. *See* Pectoralis major musculocutaneous (PMMC) flap
 Poly L-lactic acid (PLLA) mesh, 256
 Polyurethane foam, 235
 Positron emission tomography (PET), 101, 223
 Postoperative adjuvant chemotherapy, 309–310
 Postoperative radiation (therapy), 225, 287
 Potentially malignant disorders (PMDs), 84
 Precancerous condition, 12–13, 15, 18, 83
 Precancerous lesion, 12–13, 15, 18, 83
 Prefabricated reconstruction model, 268
 Prefabricated stereolithographic mandibular model (SLMM), 265
 Pregabalin, 418
 Premalignant lesions, 86
 Pressure type, 159
 Preventive dental maintenance, 352
 Prevent malignant transformation, 94
 Primary tumor (T) factor, 102, 126
 Prognosis, 87
 Prognostic factors, 221
 Proliferative verrucous leukoplakia (PVL), 86
 Protein kinase B (AKT), 65, 67
 Proton beam therapy (PBT), 298
 Psychogenic pain, 414
 Psychological aspects, 414
 Psychological status, 404
 PTEN. *See* Phosphatase and tensin homolog (PTEN)
 PTV. *See* Planning target volume (PTV)
 p21^{WAF1}, 67
- Q**
 QOL questionnaire for cancer patients treated with anticancer drugs (QOL-ACD), 408
 QOL questionnaire for general cancer, 407–408
 Quality of life (QOL), 314, 404, 414
 Quantitative measurement, 404–410
- R**
 Radial artery, 233
 Radial comitant vein, 233
 Radial forearm flap, 233–238
 Radiation caries, 339, 347–348
 Radiation-induced cancer, 298
 Radiation-induced oral mucositis, 345–347
 Radiation-induced salivary gland dysfunction, 347
 Radiation periodontal disease, 348
 Radiation xerostomia, 347
 Radical neck dissection (RND), 225
 Radiosensitivity, 285
 Radiotherapy, 321
 RAGE. *See* Receptor for advanced glycation end products (RAGE)
 RAM flap. *See* Rectus abdominis musculocutaneous (RAM) flap
 Random pattern, 247
 Ras/Raf/mitogen-activated kinase protein (MAPK), 65
 RBE. *See* Relative biological effectiveness (RBE)
 Receptor for advanced glycation end products (RAGE), 71
 Reconstruction plate, 256
 Rectus abdominis musculocutaneous (RAM) flap, 238–242, 250, 257, 258
 Recurrent laryngeal nerve, 342
 Reflex sympathetic dystrophy (RSD), 236
 Regenerating islet-derived family member 4 (Reg IV), 73
 Regenerative mandibular reconstruction, 257
 Regional recurrence, 228
 Rehabilitation, 231–232
 Relative biological effectiveness (RBE), 299
 Reliability, 405
 Religious and/or spiritual status, 404
 Rescue medication, 417
 Resection margin, 54
 Resorption patterns, 159
 Respondent and administrative burden, 405
 Responsiveness, 405
 Retropharyngeal nodes, 226
 Runt-related transcription factor 3 (RUNX3), 72, 73
 RUNX3. *See* Runt-related transcription factor 3 (RUNX3)
- S**
 S-1, 309
 Sake index, 8
 Salivary gland, 6
 tumors, 163–165
 Salivary hypofunction, 336
 Salvage, 244
 Sarcoma, 52, 166, 302, 325
 Scapular osteocutaneous flap, 257
 Scapular tip flap, 256
 SCC. *See* Spindle cell carcinoma (SCC)
 Sectional anatomy, 102
 Sectioning method, 58–59
 Segmental mandibulectomy, 188–190, 199, 265
 Selective neck dissection (SND), 225
 Sentinel lymph node, 55
 biopsy, 224
 Sequestrectomy, 339
 Serotonin noradrenaline reuptake inhibitor, 416
 Serotonin syndrome, 416
 Shoulder syndrome, 343
 Signal transducers and activators of transcription (STAT), 65, 66
 Simple dressing technique, 235–236
 Skip metastases, 223
 Smoking, 85
 index, 8
 SND. *See* Selective neck dissection (SND)
 SOBP. *See* Spread-out Bragg peak (SOBP)
 Social aspects, 414
 Social interactions, 404
 SOHND. *See* Supraomohyoid neck dissection (SOHND)
 Somatic pain, 414
 Somnolence, 416
 Spacer, 287

Speckled leukoplakia, 85, 164
 Sphincteric function, 253
 Spinal accessory nerve, 342–343
 Spindle cell carcinoma (SCC), 52, 53
 Spiritual aspects, 414
 Spontaneous pain, 417
 Spread-out Bragg peak (SOBP), 299
 Squamous cell carcinoma, 3, 4, 11, 14
 Squamous intraepithelial lesions, 86
 Squamous intraepithelial neoplasia, 86
 Staging, 56
 STAT. *See* Signal transducers and activators of transcription (STAT)
 Step-surgery concept
 initial step, 233
 touch-up step, 233
 Stereolithographic model, 267
 Sternocleidomastoid muscle flap, 250
 Submental branch, 247
 Subtotal and total maxillectomies, 194
 Subtotal-total glossectomy, 183
 Supercharged pectoralis major musculocutaneous flap (SUP-PMMC flap), 242–246
 Superficial muscular aponeurotic system (SMAS), 37, 40
 Superficial temporal artery (STA), 320
 Superficial type, 158
 Superior laryngeal nerve, 342
 SUP-PMMC flap. *See* Supercharged pectoralis major musculocutaneous flap (SUP-PMMC flap)
 Supraomohyoid neck dissection (SOHND), 225
 Surgery, 93
 Surgical guide, 265, 266
 Surgical margin, 171
 Surgical therapy, 170
 Survival and local control rates, 325
 Swallowing function, 238, 240
 Swearingen classification
 mixed type, 33
 moth-eaten type, 33
 pressure type, 33
 Sympathetic trunk, 343
 Symptoms, 157
 Systemic chemotherapy, 307–315

T

T4a, 34, 35, 37, 40, 41
 Taste disturbance, 347, 355–356
 TCAs. *See* Tricyclic antidepressants (TCAs)
 Telomerase, 67
 Telomeres, 67
 Terminal care, 414
 Therapeutic effect, 56–58
 Thoracoacromial artery, 244
 Three-dimensional computed tomography (3D-CT), 265, 267
 Three-dimensional digital model, 263–267
 3D-model, 241, 258
 3D printer, 265
 Through-and-through operation, 198
 Thyroid cartilage, 240
 Tie-over dressing, 235
 Titanium mesh, 241
 TNF α . *See* Tumor necrosis factor- α (TNF α)
 TNF-related apoptosis-inducing ligand (TRAIL), 67

Tobacco, 95
 chewing, 85
 habit, 84
 Toll-like receptors (TLRs), 69
 Tongue, 24
 cancer, 5, 34–35, 127–135, 172–184
 Tooth extraction, 353–354
 Topical bleomycin, 94
 Topical fluoride applications, 348
 Total glossectomy, 184
 Toxicities, 303
 TRAIL. *See* TNF-related apoptosis-inducing ligand (TRAIL)
 Tramadol, 416
 Tricyclic antidepressants (TCAs), 418
 Trismus, 341, 348
 Trk. *See* Tropomyosin receptor kinases (Trk)
 TrkA, 72
 TrkB, 72
 TrkC, 72
 Tropomyosin receptor kinases (Trk), 72
 Tumor necrosis factor- α (TNF α), 67

U

UFT, 309
 UICC classification, 157
 Ulcerative stomatitis, 163
 Ultrasonography (US), 101, 223
 Upper gingiva, 24
 cancer, 35, 190–195
 Urinary retention, 418
 Uterine cancer, 7

V

Vagus nerve, 342
 Validity, 405
 Vascular endothelial growth factor (VEGF), 65–69, 71, 72
 Vascular endothelial growth factor receptor (VEGFR), 67
 Venous invasion, 52
 Verbal rating scales, 415
 Vermilion, 233, 250
 Vermilion advancement flaps, 233, 250
 Verrucous carcinoma, 51, 53
 Visceral pain, 414
 Visual analogue scales, 415
 Vital staining, 171
 Vitamin A, 94
 Vomiting, 416, 417

W

Warburg effect, 69
 WHO quality of life (WHOQOL), 406
 World Health Organization (WHO), 403
 ladder, 415
 Wrap-around technique, 240, 257

X

Xerostomia, 295, 336–337

Z

Zalutumumab, 314